Stealthy biotech buys up patent portfolios in string of recent deals
Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months
Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months
The latest wireless standard hasn’t yet found its ‘killer app’ for consumers, and it’s affecting licensing negotiations
Hedonic regression is a dependable and impartial way to estimate the value of a standardised technology. Further, it can be applied to a range of products, especially those with multiple features.
The long read: Charting the value of intellectual assets can be difficult, writes Deloitte's Tim Heberden, but there are ways of showing their role as the drivers of revenue, efficiency and risk, and even in locating the value flows between them
14 April 2021
As political wrangling and potential for commercial fallout mounted, the two Korean battery suppliers reached an eleventh-hour settlement deal yesterday
12 April 2021
Saturday Opinion: Encouraging patent deals and lending through metrics and incentives could lay a trap for those who want a higher-quality patent system
03 April 2021
After IAM broke news of possible sale last year Canadian tech giant has confirmed it is in exclusive negotiations with a “North American” bidder for a part of its 38,000 asset stockpile
01 April 2021
Singapore-based PatSnap says its latest round of fundraising pushed its valuation north of $1 billion
19 March 2021
New group includes big names from the corporate IP world, representing Japanese stakeholders from both the auto and the electronics industries
17 March 2021
A strategy for protecting and exploiting data is now a must for entities involved in healthcare research
25 February 2021
How smaller biotechs can best overcome pitfalls and maximise the value of their inventions
18 February 2021
The Canadian tech giant has built a licensing operation that brings in more than $300 million annually, but those gains have failed to shift shareholder sentiment
17 February 2021
A composite index of publicly-quoted entities with largest US portfolios has enjoyed strong performance since 2018
15 February 2021
Get unlimited access to all IAM content